These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9305419)

  • 1. Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls.
    Robinson ES; Nutt DJ; Jackson HC; Hudson AL
    J Psychopharmacol; 1997; 11(3):259-69. PubMed ID: 9305419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the functional role in behavior of the neuromediator receptor by antisense knockdown of its gene expression].
    Dygalo NN; Kalinina TS; Shishkina GT
    Ross Fiziol Zh Im I M Sechenova; 2000 Oct; 86(10):1278-82. PubMed ID: 11200328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of the antisense oligonucleotide technique in neuropsychopharmacology research].
    Yamada M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):129-38. PubMed ID: 8905802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides in the study of central mechanisms of the cardiovascular regulation.
    Culman J
    Exp Physiol; 2000 Nov; 85(6):757-67. PubMed ID: 11187969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo.
    Probst JC; Skutella T
    Biochem Biophys Res Commun; 1996 Aug; 225(3):861-8. PubMed ID: 8780703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of antisense inhibition of brain G-protein-coupled receptor function.
    Van Oekelen D; Luyten WH; Leysen JE
    Brain Res Brain Res Rev; 2003 May; 42(2):123-42. PubMed ID: 12738054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides for target validation in the CNS.
    Ho SP; Hartig PR
    Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems.
    Nicot A; Pfaff DW
    J Neurosci Methods; 1997 Jan; 71(1):45-53. PubMed ID: 9125374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
    Standaert DG; Testa CM; Rudolf GD; Hollingsworth ZR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):342-52. PubMed ID: 8558453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense studies of brain GABAA receptors.
    Karle J
    Dan Med Bull; 2002 May; 49(2):130-44. PubMed ID: 12064090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense targeting in behavioural neuroendocrinology.
    Landgraf R
    J Endocrinol; 1996 Dec; 151(3):333-40. PubMed ID: 8994378
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
    Zhou LW; Zhang SP; Qin ZH; Weiss B
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANTISENSE oligonucleotides: a new tool in neuroscience.
    Pilowsky PM; Suzuki S; Minson JB
    Clin Exp Pharmacol Physiol; 1994 Dec; 21(12):935-44. PubMed ID: 7736652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific block of androgen receptor activity by antisense oligonucleotides.
    Hamy F; Brondani V; Spoerri R; Rigo S; Stamm C; Klimkait T
    Prostate Cancer Prostatic Dis; 2003; 6(1):27-33. PubMed ID: 12664061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense inhibition of the renin-angiotensin system in brain and peripheral organs.
    Mohuczy D; Phillips MI
    Methods; 2000 Nov; 22(3):197-209. PubMed ID: 11071815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomic and molecular principles of psychopharmacology. A primer for psychiatrists.
    Heckers S; Konradi C
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):1-22. PubMed ID: 10674188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.